We recently published 7 Best ASX Stocks to Buy Right Now. Immuron Limited (NASDAQ:IMRN) is one of the best ASX stocks.
Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also developing similar medicines. Its shares were dealt a hefty setback on Wednesday when they closed 25.8% lower after the firm announced that its clinical trial for an ETEC hyperimmune bovine colostrum product had failed to reach a statistically significant level for its primary endpoint. The study was conducted by the Uniformed Services University to evaluate the product for maintaining gut health during travel and deployment. Immuron Limited (NASDAQ:IMRN) asserted that since the product was not administered according to the rules that apply to its Travelan product and was manufactured by a third party, the firm did not consider the results to reflect Travelan’s performance.
Copyright: mikkolem / 123RF Stock Photo
In other news, on November 5th, the Food and Drug Administration (FDA) cleared Immuron Limited (NASDAQ:IMRN)’s IMM-529 drug for a phase 2 clinical trial. IMM-529 is for patients with Clostridioides difficile infection, a disease of the gut that causes diarrhea, abdominal pain, fever, and other symptoms. The study is expected to commence in the first half of 2026 and enroll as many as 60 participants who are suffering from the disease for the first time or experiencing a recurring episode.
While we acknowledge the potential of IMRN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
